Viatris Introduces Effexor® in Japan as Innovative Treatment for GAD

Viatris Unveils Effexor® for Generalized Anxiety Disorder in Japan

In a significant stride for mental health treatment in Japan, Viatris Inc., listed on Nasdaq as VTRS, has announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules, a serotonin-noradrenaline reuptake inhibitor (SNRI), specifically for adults suffering from generalized anxiety disorder (GAD). This marks a historic moment as it becomes the first and only approved medication in Japan dedicated solely to treating this prevalent mental health condition.

The approval of Effexor® addresses a crucial gap in mental health care within Japan, considering that GAD is one of the most common and debilitating disorders, adversely affecting the daily lives of those afflicted. Data from recent studies indicates that approximately 7.6% of the Japanese population might be living with this condition, pointing to a critical need for effective therapeutic options.

Philippe Martin, the Chief R&D Officer at Viatris, emphasized the importance of this approval, stating that it reflects the company's commitment to delivering innovative healthcare solutions that align with their strategic vision. “The launch of Effexor® showcases our capability to navigate regulatory landscapes successfully and to provide solutions for unmet medical needs in Japan,” he noted.

The efficacy of Effexor® was demonstrated in a Phase 3 clinical trial conducted in Japan. This randomized, placebo-controlled study confirmed the superior anxiolytic effects of venlafaxine compared to placebo over an eight-week period, based on significant changes in the Hamilton Anxiety Rating Scale (HAM-A) scores. Remarkably, this study not only met its primary objectives but also achieved all seven secondary efficacy conclusions outlined by the protocol, showcasing the drug's potential in real-world applications.

Moreover, the safety profile for Effexor® was consistent with previous findings, exhibiting low discontinuation rates due to treatment-related side effects. In the study, only 7.3% of participants discontinued treatment due to adverse events, significantly lower than the 1.7% observed in the placebo group.

As the treatment landscape evolves, Corinne Le Goff, Viatris' Chief Commercial Officer, expressed optimism about the future. She stated, “This approval is pivotal in expanding access to effective treatment for adults grappling with GAD in Japan. Our team stands ready to utilize our established infrastructure and expertise to ensure that patients can access this necessary therapy without delay.”

Effexor®'s newly acquired approval in Japan adds to its existing global presence, with the medication already available in over 80 countries for managing GAD, along with its prior approval for major depressive disorder in Japanese adults.

Understanding Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder is characterized by pervasive and chronic anxiety or excessive worry about various aspects of life, from work to health. An afflicted individual commonly experiences multiple symptoms, including fatigue, irritability, sleep disturbances, muscle tension, and difficulty concentrating, severely impairing daily functioning. The World Health Organization indicates that 2.6% of Japan's population will encounter GAD at some stage in their lives, highlighting the urgency for effective medical interventions.

Currently, Viatris is not only focusing on GAD but has also developed a portfolio of innovative products in Japan. Their offerings encompass Spydia® Nasal Spray for status epilepticus and ongoing clinical trials for other treatments targeting various health conditions, reflecting the company’s commitment to advancing healthcare across multiple fronts.

Furthermore, Viatris operates with a mission to empower health at every life stage, underscoring their dedication to meeting patient needs worldwide through innovative solutions. Headquartered in the U.S., with significant centers in Pittsburgh, Shanghai, and Hyderabad, Viatris continues to broaden its impact, ensuring access to essential therapies for patients globally.

This recent approval of Effexor® is not just a corporate milestone for Viatris; it is a beacon of hope for many living with generalized anxiety disorder in Japan, marking the beginning of a new chapter in mental health treatment.